S19-Gender analysis of clinical practice guidelines
for depression from four European countries: Austria, Finland, Sweden, and the United Kingdom Sanna Lö nnfors, MSPH (Charité Universitä tsmedizin Berlin, Berlin, Germany); Birgit Babitsch, DrPH (Berlin School of Public Health, Berlin, Germany); Susanne Weinbrenner, MD (Presenter) (German Agency for Quality in Medicine, Berlin, Germany) PRIMARY TRACK: Guideline development SECONDARY TRACK: Equity in guidelines BACKGROUND (INTRODUCTION): Depression is one of the most common psychiatric disorders and leading causes of disability worldwide. There is evidence that women suffer from depression more often than men and have different symptoms and coping strategies. The reasons for the gender differences are not fully understood. This study was done as a Master's Thesis in Public Health. Its objective was to analyze the gender sensitivity of clinical practice guidelines for depression from Austria, Finland, Sweden, and the United Kingdom.
LEARNING OBJECTIVES (TRAINING GOALS):
1. Identify lacks of gender aspect in existing guidelines for depression. 2. Give recommendations for including gender aspect in guidelines for depression. METHODS: Gender analysis was conducted using two approaches: 1) counting sex/gender-related words; 2) detailed analysis based on a literature review. Firstly, 10 gender-related words were listed in respective languages and searched for in the guidelines. The number of hits was compared with the total number of words in the guideline. Secondly, current literature on gender differences in depression was searched in PubMed and Embase databases and reviewed. Six key categories (epidemiology; symptoms; suicide; diagnosis, treatment and prevention; social factors; coping strategies) were recognized. Gender differences in each category found in literature were summarized and used as a template to search for these issues in the guidelines. A scoring system was created and applied. RESULTS: Clear gender differences in depression exist. However, with few exemptions, most were not mentioned in the guidelines. The Finnish and British guidelines mentioned depression being more common in women. No guideline mentioned gender-specific symptoms. The Austrian guideline gave gender-specific suicide rates and the Finnish guideline listed The process from an evidence-based conclusion to the formulation of a recommendation is often not transparent. Recommendations are based on conclusions (evidence from literature) and 'other considerations' (patient preferences and organizational issues). It is often not clear which 'other considerations' have been taken into account and to what extent these have contributed to the recommendation. A recently developed tool was applied to judge 'other considerations' in a structured way and to transparently report how the recommendation was formulated. (Grant from ZonMw) LEARNING OBJECTIVES (TRAINING GOALS): 1. To get an overview of 'other considerations' that play a role in the process of conclusion to recommendation. 2. To gain insight in the development of a tool to incorporate 'other considerations' in a structured and transparent way to formulate the recommendation. 3. To gain insight in the experiences with the tool to include 'other considerations' in a structured and transparent way to formulate the recommendation.
4. To learn how to apply this tool in practice during guideline development.
METHODS:
The tool, consisting of a checklist of 'other considerations' and an instrument for grading recommendations, has been applied by the guideline working group drafting the revision of the evidence-based guideline on renal cell carcinoma. A literature search and synthesis of the evidence regarding 'other considerations' were carried out. RESULTS: The experiences of the guideline working group and the methodologist with the applied tool, as well as the search results and synthesis of the evidence on the 'other considerations,' were collected and evaluated. By using the tool to incorporate these considerations, it was transparent as to which were included in and how this affected the final recommendation. The revised guideline will be distributed to stakeholders to gain information on their perception of the process and results.
DISCUSSION (CONCLUSION):
Based on the experiences and commentaries of the guideline working group, methodologists, stakeholders, and users of the guideline, suggestions for improvement of the tool were extracted. After applying relevant changes, the tool will be implemented in oncologic guidelines within the Netherlands. Other organizations are invited to use this tool, which may lead to more structured and transparent guideline development. TARGET AUDIENCE(S): 1. Guideline developer 2. Guideline implementer 3. Developer of guideline-based products 4. Quality improvement manager/facilitator 5. Medical educator 6. Health care policy analyst/policymaker 7. Health insurance payers and purchasers 8. Medical providers and executives 9. Allied health professionals 10. Consumers' and patients' representatives 11. Nurses
